Pharma BD Deal Intelligence

Johnson & Johnson / Sail Biomedicines, Inc.

2026 · Licensing/Option · $3.4B · Pending

Johnson & Johnson entered strategic agreements with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases, with an exclusive option to acquire Sail. J&J makes total initial payments of $785 million, including a $465 million equity investment, plus $140 million in contingent development milestone payments; exercising the acquisition option would trigger an additional $2.58 billion payment. Sail's platform is designed to generate CAR-T cells directly in the body, avoiding ex vivo cell manufacturing. J&J guided to adjusted EPS dilution of roughly $0.18 in 2026 and $1.28 in 2027 assuming option exercise.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Johnson & Johnson deals